Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer’s Disease

Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev and Ilya Bezprozvanny
Molecular Pharmacology April 2019, 95 (4) 337-348; DOI: https://doi.org/10.1124/mol.118.114348
Elena Popugaeva
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daria Chernyuk
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hua Zhang
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatyana Y. Postnikova
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karina Pats
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Fedorova
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Poroikov
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleksey V. Zaitsev
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilya Bezprozvanny
Laboratory of Molecular Neurodegeneration, Department of Medical Physics, Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation (E.P., D.C., I.B.); Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (H.Z., I.B.); Laboratory of Molecular Mechanisms of Neural Interactions, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russian Federation (T.Y.P., A.V.Z.); VVS Laboratory Inc., Ulica Dostoevskogo 44, St. Petersburg, Russian Federation (K.P., E.F.); Institute of Biomedical Chemistry, Moscow, Russian Federation (V.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Chemical structures of potential TRPC6 modulators identified as a result of bioinformatics search. (A) HYP-9, (B) compound 64402, (C) compound 50741, and (D) compound 51164. Compounds 64402, 50741, and 51164 were found in the InterBioScreen library.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Evaluation of protective effects of HYP9 and compound 64402 in conditions of amyloid synaptotoxicity. (A) Representative confocal images of day 14 of in vitro cultivation hippocampal neurons transfected with tdTomato plasmid. Images for control (CTRL) cultures and cultures exposed to oligomeric Aβ42 are shown as indicated. HPF was added at the concentration of 300 nM, HYP9 was tested at concentrations of 100 nM and 1 µM as indicated, compound 64402 was tested at the 1 µM concentration. (B) The average percentages of mushroom spines (%MS) in each experimental condition are present as mean ± S.D. (n ≥ 16 neurons for each group). Untreated hippocampal cultures (CTRL) are shown as the filled bar. Open bars correspond to hippocampal cultures that were treated with oligomeric Aβ42. *P < 0.05; ***P < 0.0005 by one-way ANOVA, following Dunn-Sidak post hoc test.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Evaluation of protective effects of compound 50741 in conditions of amyloid synaptotoxicity. (A) Representative confocal images of day 14 of in vitro cultivation hippocampal neurons transfected with tdTomato plasmid. Images for control (CTRL) cultures and cultures exposed to oligomeric Aβ42 are shown as indicated. HPF was added at the concentration of 30 nM, compound 50741 was tested at concentrations of 1, 10, 30, and 100 nM as indicated. Scale bar, 10 µm. (B) The average percentages of mushroom spines (%MS) in each experimental condition are present as mean ± S.D. (n = 22–32 neurons for each group). Untreated hippocampal cultures (CTRL) are shown as filled bars. Open bars correspond to hippocampal cultures that were treated with oligomeric Aβ42. **P < 0.005; ***P < 0.0005 by two-way ANOVA with Dunn-Sidak post hoc test.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Evaluation of the protective effects of compound 51164 in conditions of amyloid synaptotoxicity. (A) Representative confocal images of day 14 of in vitro cultivation hippocampal neurons transfected with tdTomato plasmid. Images for control (CTRL) cultures and cultures exposed to oligomeric Aβ42 (Aβ) are shown as indicated. HPF was added at the concentration of 30 nM, compound 51164 was tested at concentrations of 1, 10, 30, and 100 nM as indicated. Scale bar, 10 µm. (B) The average percentages of mushroom spines (%MS) in each experimental condition are present as mean ± S.D. (n = 22–32 neurons for each group). Untreated hippocampal cultures (CTRL) are shown as filled bars. Open bars correspond to hippocampal cultures that were treated with oligomeric Aβ42. *P < 0.05; ***P < 0.0005 by two-way ANOVA with Dunn-Sidak post hoc test.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Compound 51164 acts as a positive modulator of TRPC6 channels. (A) Time course of Fura-2 fluorescence Ca2+ signals (340/380 ratio) is shown for HEK293 cells transfected with EGFP + TRPC6 plasmids. Traces from individual cells are shown as thin gray lines, and average traces are shown as thick black lines. Cells were incubated in aCSF medium containing 2 mM Ca2+. The time of addition of 10 µM HPF or 30 µM of compound 51164 is indicated by black bars above the Fura-2 traces. (B) Average amplitude of Ca2+ influx peak is shown as the change in 340/380 Fura-2 ratio signals for the cells exposed to HPF or compound 51164. The results are presented as mean ± S.D. (n = 40 cells). ***P < 0.0001 by two-way ANOVA with Tukey’s post hoc test. (C) Time course of Fura-2 fluorescence Ca2+ signals (340/380 ratio) is shown for HEK293 cells transfected with EGFP (GFP) or EGFP + TRPC6 (TRPC6) plasmids as indicated. Traces from individual cells are shown as thin gray lines, and average traces are shown as thick black lines. Cells were moved to modified aCSF medium containing 0.1 mM Ca2+ for 2 minutes, and then returned to the medium containing 2 mM Ca2+ with the addition of 50 µM of OAG. The time of addition of 30 µM of compound 51164 is indicated by black bars above the Fura-2 traces. (D) Average amplitude of Ca2+ influx peak is shown as the change in 340/380 Fura-2 ratio signals for each group of cells tested in experiments shown in (C). The results are presented as mean ± S.D. (n = 40 cells). ***P < 0.0001 by two-way ANOVA with Tukey’s post hoc test.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Compound 51164 rescues Aβ42-supressed nSOCE in hippocampal postsynaptic dendritic spines. (A–I) The time course of GCaMP5.3 fluorescence signal changes in the spines of hippocampal neurons at day 14 of in vitro cultivation. Neurons were preincubated in Ca2+ free media, and 10 mM Ca2+ was added as indicated by the black bar above the traces. The experiments were performed in the presence of a drug cocktail of Ca2+ inhibitors as described in Materials and Methods. The presence of 300 nM HPF or 300 nM of compound 51164 is indicated above the GCaMP5.3 traces. For each experimental group, individual spine (thin gray lines) and average (thick black lines) fluorescence traces are shown. Results with control (CTRL) neurons are shown in (A–C). Results with neurons preincubated with Aβ42 oligomers (Aβ) are shown in (D–F) as indicated. Results depicted in (A–F) were obtained in the presence of control shRNA (CTRLsh). Results with neurons transfected with shTRPC6 (T6sh) plasmids are shown in (G–I). (J) The average nSOCE spine peak amplitude is shown for each group of cells depicted in (A–I). The F/F0 changes in GCaMP5.3 fluorescence are presented as mean ± S.D. (n = 20 spines),*P < 0.05; ***P < 0.0005 by Kruskal-Wallis ANOVA.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Compound 51164 recovers LTP induction in slices from 6-month-old 5xFAD mice. (A and C) LTP is not altered in hippocampal slices from 2-month-old 5xFAD mice. Incubation of slices with 100 nM of compound 51164 does not influence LTP induction in slices from 2-month-old WT and 5xFAD mice (3–5 mice per group). Two-way ANOVA, F1,14 = 0.64, P = 0.44 [WT (n = 4 slices); WT (compound 51164) (n = 5); 5xFAD (n = 3); 5xFAD (compound 51164) (n = 6)]. (B and D) LTP is impaired in hippocampal slices from 6-month-old 5xFAD mice. Incubation of 5xFAD slices from 6-month-old 5xFAD mice with 100 nM of compound 51164 recovers LTP induction. Two-way ANOVA following Tukey’s post hoc test, F1,31 = 6.31, P = 0.02. In 6-month-old WT slices compound 51164 does not change LTP (P = 0.99) [WT (n = 8); WT (compound 51164) (n = 6); 5xFAD (n = 12); 5xFAD (compound 51164) (n = 9)]. *P < 0.05; **P < 0.01].

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    List of TRPC6 agonists from the Clarivate Analytics Integrity database

    Integrity IDIUPAC NameStructural FormulaMolecular MechanismTherapeutic Group
    HYP-12,4-Bis(3-methylbutyryl)phloroglucinol 2,4-bis(3-methylbutyryl)-1,3,5-trihydroxybenzeneEmbedded Image1) TRPC6 agonists; 2) leukotriene CysLT1 (LTD4) antagonists; 3) antagonists free fatty acid receptor 1 (FFAR1; PR40); 4) agonists signal transduction modulators; 5) prostanoid thromboxane receptors antagonists; and 6) leukotriene antagonists1) Antiallergy/antiasthmatic drugs; 2) antiviral; and 3) agents for type 2 diabetes
    HYP-51,1′-(2,4,6-Trihydroxybenzene-1,3-diyl)bis(4-methylpentan-1-one)Embedded Image1) TRPC6 Agonists1) Treatment of cognition disorders
    HYP-91,1′-(2,4,6-Trihydroxybenzene-1,3-diyl)dihexan-1-oneEmbedded Image1) TRPC6 Agonists1) Treatment of cognition disorders
    830288[4-(5-Chloro-2-methylphenyl)piperazin-1-yl](3-fluorophenyl)methanoneEmbedded Image1) TRPC6 Agonists1) Psychiatric disorders (not specified); and 2) treatment of neurodegenerative diseases
    871099N-(2-Chlorophenyl)-2-[4-(2,3-dimethylphenyl)piperazin-1-yl]acetamide trifluoroacetateEmbedded Image1) TRPC6 agonists; and 2) TRPC3 agonists1) Psychiatric disorders (not specified); and 2) treatment of neurodegenerative diseases
    8803952-[4-(2,3-Dimethylphenyl)piperazin- 1-yl]-N-(2-fluorophenyl)acetamide trifluoroacetateEmbedded Image1) TRPC6 agonists; and 2) TRPC3 agonists1) Psychiatric disorders (not specified); and 2) treatment of neurodegenerative diseases
    • ID, identification; IUPAC, International Union of Pure and Applied Chemistry.

    • View popup
    TABLE 2

    Biologic activities of selected compounds predicted by the PASS Online web service for the mechanism of action

    Mechanism of ActionCompound Number
    Hyp9644025074151164
    Structure identity (%)10010091.8291.8290.2490.2488.1288.12
    AnalogHyp9Hyp9HYP1HYP1880395880395871099871099
    ActivityPaPiPaPiPaPiPaPi
    Calcium channel (voltage-sensitive) activator0.5400.0520.5460.0480.4940.0830.6240.017
    Neuropeptide Y2 antagonist0.2290.1590.2170.1770.5710.0080.6290.004
    Sigma receptor agonist0.1570.1460.1980.1350.2880.0820.4840.028
    Calcium channel activator0.2240.1040.2910.0380.3380.0260.3680.018
    Acetylcholine neuromuscular blocking agent——0.5990.0230.4840.0840.4810.087
    • —, no data available.

    • View popup
    TABLE 3

    Biologic activities of selected compounds predicted by the PASS Online web service possible adverse and toxic effects

    Adverse and Toxic EffectCompound Number
    Hyp9644025074151164
    ActivityPaPiPaPiPaPiPaPi
    Gastrointestinal hemorrhage0.6950.0260.7140.0210.3890.1570.6150.050
    Multiple organ failure0.6000.0600.6770.0370.3940.1560.7620.018
    Toxic vascular/respiration0.798v0.018v0.885r0.019r0.096v0.403v0.254v0.241v
    Carcinogenic. group 10.3060.0550.3570.0330.1150.4010.2000.161
    Cardiodepressant0.4910.0210.4550.0260.0440.3420.1960.145
    Carcinogenic. group 2A0.1550.0990.1980.0640.0570.2420.1690.087
    • r, respiration; v, vascular.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    • Supplemental Data -

      Supplemental 1 - List of analogues of TRPC6 agonists obtained from InterBioScreen ltd.


    • Supplemental Data -


      Supplemental Table 1 - Integrity product report


PreviousNext
Back to top

In this issue

Molecular Pharmacology: 95 (4)
Molecular Pharmacology
Vol. 95, Issue 4
1 Apr 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer’s Disease
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Piperazines as Potential Neuroprotective Agents

Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev and Ilya Bezprozvanny
Molecular Pharmacology April 1, 2019, 95 (4) 337-348; DOI: https://doi.org/10.1124/mol.118.114348

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Piperazines as Potential Neuroprotective Agents

Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev and Ilya Bezprozvanny
Molecular Pharmacology April 1, 2019, 95 (4) 337-348; DOI: https://doi.org/10.1124/mol.118.114348
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Material and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics